Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

Kazuhisa Furue, Takamichi Ito, Masutaka Furue

研究成果: ジャーナルへの寄稿評論記事

9 引用 (Scopus)

抄録

Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

元の言語英語
ページ(範囲)182-188
ページ数7
ジャーナルCytokine
111
DOI
出版物ステータス出版済み - 11 2018

Fingerprint

Interleukin-23
Psoriatic Arthritis
Interleukin-17
Psoriasis
Skin
Biological Products
Synovial Membrane
Joints
Psychology

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Hematology
  • Molecular Biology

これを引用

Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. / Furue, Kazuhisa; Ito, Takamichi; Furue, Masutaka.

:: Cytokine, 巻 111, 11.2018, p. 182-188.

研究成果: ジャーナルへの寄稿評論記事

@article{f0559552d3594723be02fdf517f3f7df,
title = "Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis",
abstract = "Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.",
author = "Kazuhisa Furue and Takamichi Ito and Masutaka Furue",
year = "2018",
month = "11",
doi = "10.1016/j.cyto.2018.08.025",
language = "English",
volume = "111",
pages = "182--188",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis

AU - Furue, Kazuhisa

AU - Ito, Takamichi

AU - Furue, Masutaka

PY - 2018/11

Y1 - 2018/11

N2 - Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

AB - Psoriasis and psoriatic arthritis cause significant physical and psychological burdens for afflicted individuals. An accelerated TNF-α/IL-23/IL-17 axis is their major pathomechanism; therefore, anti-TNF-α/IL-23/IL-17 biologics are very effective for the treatment of skin and joint lesions in psoriasis and psoriatic arthritis. Given that the IL-17 signature is more upregulated in the skin than in synovium in psoriatic arthritis, anti-IL-23/IL-17 agents seem to be superior to anti-TNF-α remedies in the treatment of skin lesions. In this review, we focus on the differential efficacy of anti-TNF-α/IL-23/IL-17 biologics in psoriasis and psoriatic arthritis.

UR - http://www.scopus.com/inward/record.url?scp=85052470976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052470976&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2018.08.025

DO - 10.1016/j.cyto.2018.08.025

M3 - Review article

C2 - 30172115

AN - SCOPUS:85052470976

VL - 111

SP - 182

EP - 188

JO - Cytokine

JF - Cytokine

SN - 1043-4666

ER -